AAPL343.20-0.26 (-0.08%) ▼|ABBV283.13-2.29 (-0.80%) ▼|ABT104.06-0.83 (-0.79%) ▼|ACN236.90+7.22 (+3.14%) ▲|ADBE247.09+1.89 (+0.77%) ▲|AMAT413.11+3.82 (+0.93%) ▲|AMD538.05+9.30 (+1.76%) ▲|AMGN424.94-7.55 (-1.75%) ▼|AMT183.05-2.22 (-1.20%) ▼|AMZN262.45+12.45 (+4.98%) ▲|AVGO334.59+5.84 (+1.78%) ▲|AXP316.37+2.78 (+0.88%) ▲|BA191.51+1.30 (+0.68%) ▲|BAC50.39-0.84 (-1.64%) ▼|BKNG162.60-0.85 (-0.52%) ▼|BLK1,124.83-9.56 (-0.84%) ▼|BMY58.84-0.91 (-1.52%) ▼|BNY142.41-0.89 (-0.62%) ▼|BRK-B532.47+0.45 (+0.08%) ▲|C121.72-2.54 (-2.04%) ▼|CAT725.77-4.99 (-0.68%) ▼|CL93.40-0.71 (-0.75%) ▼|CMCSA21.90+0.00 (+0.00%) ▲|COF199.86-1.88 (-0.93%) ▼|COP145.21-1.30 (-0.89%) ▼|COST995.53+6.42 (+0.65%) ▲|CRM242.46+1.76 (+0.73%) ▲|CSCO106.50-0.89 (-0.83%) ▼|CVS92.68+0.32 (+0.34%) ▲|CVX224.48-0.51 (-0.23%) ▼|DE627.30-14.56 (-2.27%) ▼|DHR224.39-4.65 (-2.03%) ▼|DIS109.58-1.01 (-0.91%) ▼|DUK119.26-2.21 (-1.82%) ▼|EMR160.52-0.95 (-0.59%) ▼|FDX293.81+0.26 (+0.09%) ▲|GD341.40-2.83 (-0.82%) ▼|GE311.34-2.49 (-0.79%) ▼|GEV908.35-12.85 (-1.39%) ▼|GILD153.07-3.12 (-2.00%) ▼|GM82.72-1.24 (-1.48%) ▼|GOOG340.16+3.25 (+0.96%) ▲|GOOGL344.18+3.59 (+1.05%) ▲|GS875.79-5.47 (-0.62%) ▼|HD309.99+0.36 (+0.12%) ▲|HON209.98-1.43 (-0.68%) ▼|IBM236.36+4.22 (+1.82%) ▲|INTC92.03+2.18 (+2.43%) ▲|INTU325.62+0.47 (+0.14%) ▲|ISRG433.18+6.48 (+1.52%) ▲|JNJ253.96-1.60 (-0.63%) ▼|JPM333.63-6.09 (-1.79%) ▼|KO93.44-0.47 (-0.50%) ▼|LIN503.44+5.01 (+1.01%) ▲|LLY1,240.40-16.63 (-1.32%) ▼|LMT548.45-3.64 (-0.66%) ▼|LOW195.90-1.48 (-0.75%) ▼|LRCX272.20+8.26 (+3.13%) ▲|MA616.27-1.15 (-0.19%) ▼|MCD242.63-0.34 (-0.14%) ▼|MDLZ63.34-0.57 (-0.89%) ▼|MDT92.74-2.01 (-2.12%) ▼|META705.44-3.89 (-0.55%) ▼|MMM162.10-2.65 (-1.61%) ▼|MO74.07-1.05 (-1.39%) ▼|MRK143.67-2.28 (-1.56%) ▼|MS178.49-2.08 (-1.15%) ▼|MSFT533.52+4.47 (+0.84%) ▲|MU904.90+26.06 (+2.97%) ▲|NEE78.18-1.62 (-2.03%) ▼|NFLX69.85-0.68 (-0.96%) ▼|NKE37.22+0.09 (+0.24%) ▲|NOW145.35+3.38 (+2.38%) ▲|NVDA217.09+2.96 (+1.38%) ▲|ORCL129.63+1.40 (+1.09%) ▲|PEP133.57+2.08 (+1.58%) ▲|PFE29.43-0.15 (-0.51%) ▼|PG157.71-1.64 (-1.03%) ▼|PLTR194.15+8.12 (+4.36%) ▲|PM200.98-4.22 (-2.06%) ▼|QCOM173.53+1.42 (+0.83%) ▲|RTX192.11-1.81 (-0.93%) ▼|SBUX97.87+0.35 (+0.36%) ▲|SCHW89.58-2.38 (-2.59%) ▼|SO89.27-1.91 (-2.09%) ▼|SPG202.49-2.95 (-1.44%) ▼|T23.20-0.24 (-1.02%) ▼|TMO679.28-10.72 (-1.55%) ▼|TMUS156.09-3.01 (-1.89%) ▼|TSLA368.06+13.34 (+3.76%) ▲|TXN276.15-0.33 (-0.12%) ▼|UBER69.96-0.39 (-0.55%) ▼|UNH406.88+5.45 (+1.36%) ▲|UNP287.01-2.03 (-0.70%) ▼|UPS97.46-0.02 (-0.02%) ▼|USB57.85-0.88 (-1.50%) ▼|V402.92+0.31 (+0.08%) ▲|VZ44.15-0.64 (-1.43%) ▼|WFC81.80-2.07 (-2.47%) ▼|WMT118.70-0.11 (-0.09%) ▼|XOM178.28-0.70 (-0.39%) ▼|AAPL343.20-0.26 (-0.08%) ▼|ABBV283.13-2.29 (-0.80%) ▼|ABT104.06-0.83 (-0.79%) ▼|ACN236.90+7.22 (+3.14%) ▲|ADBE247.09+1.89 (+0.77%) ▲|AMAT413.11+3.82 (+0.93%) ▲|AMD538.05+9.30 (+1.76%) ▲|AMGN424.94-7.55 (-1.75%) ▼|AMT183.05-2.22 (-1.20%) ▼|AMZN262.45+12.45 (+4.98%) ▲|AVGO334.59+5.84 (+1.78%) ▲|AXP316.37+2.78 (+0.88%) ▲|BA191.51+1.30 (+0.68%) ▲|BAC50.39-0.84 (-1.64%) ▼|BKNG162.60-0.85 (-0.52%) ▼|BLK1,124.83-9.56 (-0.84%) ▼|BMY58.84-0.91 (-1.52%) ▼|BNY142.41-0.89 (-0.62%) ▼|BRK-B532.47+0.45 (+0.08%) ▲|C121.72-2.54 (-2.04%) ▼|CAT725.77-4.99 (-0.68%) ▼|CL93.40-0.71 (-0.75%) ▼|CMCSA21.90+0.00 (+0.00%) ▲|COF199.86-1.88 (-0.93%) ▼|COP145.21-1.30 (-0.89%) ▼|COST995.53+6.42 (+0.65%) ▲|CRM242.46+1.76 (+0.73%) ▲|CSCO106.50-0.89 (-0.83%) ▼|CVS92.68+0.32 (+0.34%) ▲|CVX224.48-0.51 (-0.23%) ▼|DE627.30-14.56 (-2.27%) ▼|DHR224.39-4.65 (-2.03%) ▼|DIS109.58-1.01 (-0.91%) ▼|DUK119.26-2.21 (-1.82%) ▼|EMR160.52-0.95 (-0.59%) ▼|FDX293.81+0.26 (+0.09%) ▲|GD341.40-2.83 (-0.82%) ▼|GE311.34-2.49 (-0.79%) ▼|GEV908.35-12.85 (-1.39%) ▼|GILD153.07-3.12 (-2.00%) ▼|GM82.72-1.24 (-1.48%) ▼|GOOG340.16+3.25 (+0.96%) ▲|GOOGL344.18+3.59 (+1.05%) ▲|GS875.79-5.47 (-0.62%) ▼|HD309.99+0.36 (+0.12%) ▲|HON209.98-1.43 (-0.68%) ▼|IBM236.36+4.22 (+1.82%) ▲|INTC92.03+2.18 (+2.43%) ▲|INTU325.62+0.47 (+0.14%) ▲|ISRG433.18+6.48 (+1.52%) ▲|JNJ253.96-1.60 (-0.63%) ▼|JPM333.63-6.09 (-1.79%) ▼|KO93.44-0.47 (-0.50%) ▼|LIN503.44+5.01 (+1.01%) ▲|LLY1,240.40-16.63 (-1.32%) ▼|LMT548.45-3.64 (-0.66%) ▼|LOW195.90-1.48 (-0.75%) ▼|LRCX272.20+8.26 (+3.13%) ▲|MA616.27-1.15 (-0.19%) ▼|MCD242.63-0.34 (-0.14%) ▼|MDLZ63.34-0.57 (-0.89%) ▼|MDT92.74-2.01 (-2.12%) ▼|META705.44-3.89 (-0.55%) ▼|MMM162.10-2.65 (-1.61%) ▼|MO74.07-1.05 (-1.39%) ▼|MRK143.67-2.28 (-1.56%) ▼|MS178.49-2.08 (-1.15%) ▼|MSFT533.52+4.47 (+0.84%) ▲|MU904.90+26.06 (+2.97%) ▲|NEE78.18-1.62 (-2.03%) ▼|NFLX69.85-0.68 (-0.96%) ▼|NKE37.22+0.09 (+0.24%) ▲|NOW145.35+3.38 (+2.38%) ▲|NVDA217.09+2.96 (+1.38%) ▲|ORCL129.63+1.40 (+1.09%) ▲|PEP133.57+2.08 (+1.58%) ▲|PFE29.43-0.15 (-0.51%) ▼|PG157.71-1.64 (-1.03%) ▼|PLTR194.15+8.12 (+4.36%) ▲|PM200.98-4.22 (-2.06%) ▼|QCOM173.53+1.42 (+0.83%) ▲|RTX192.11-1.81 (-0.93%) ▼|SBUX97.87+0.35 (+0.36%) ▲|SCHW89.58-2.38 (-2.59%) ▼|SO89.27-1.91 (-2.09%) ▼|SPG202.49-2.95 (-1.44%) ▼|T23.20-0.24 (-1.02%) ▼|TMO679.28-10.72 (-1.55%) ▼|TMUS156.09-3.01 (-1.89%) ▼|TSLA368.06+13.34 (+3.76%) ▲|TXN276.15-0.33 (-0.12%) ▼|UBER69.96-0.39 (-0.55%) ▼|UNH406.88+5.45 (+1.36%) ▲|UNP287.01-2.03 (-0.70%) ▼|UPS97.46-0.02 (-0.02%) ▼|USB57.85-0.88 (-1.50%) ▼|V402.92+0.31 (+0.08%) ▲|VZ44.15-0.64 (-1.43%) ▼|WFC81.80-2.07 (-2.47%) ▼|WMT118.70-0.11 (-0.09%) ▼|XOM178.28-0.70 (-0.39%) ▼|
18 C
New York
Monday, October 19, 2026

Tag: biologics

newssourceFORcompanycontentinformation1releasesmarket

Laboratory Filtration Market Eyes US$ 6.8 Bn by 2030: Latest Report by Wissen Research

SHERIDAN, Wyo., June 15, 2026 /PRNewswire/ -- The global laboratory filtration market is projected to grow from USD 4.5 billion in 2025 to USD...

Stem Cell Therapy Market worth $3.65 billion by 2035 | MarketsandMarkets™

DELRAY BEACH, Fla., June 15, 2026 /PRNewswire/ -- According to MarketsandMarkets™, the Stem Cell Therapy Market is projected to grow from about USD 0.48 billion...

Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2...

– Verekitug, administered once every three months, led to clinically meaningful improvements in nasal polyp score (NPS) in approximately 80% of participants –

New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myeloma

TALVEY® plus DARZALEX FASPRO® with or without pomalidomide showed progression-free survival of up to 81% and overall survival of up to 89% at 24 monthsMonumenTAL-3 is the...

BRC Therapeutics Appoints Ron Eastman to Board of Directors

Veteran Pharma Executive and Healthcare Investor Brings More Than 40 Years of Drug Development, Operations and Investment ExperienceMONTEREY, Calif., June 12, 2026 /PRNewswire/ -- BRC...

Sustainable Pharmaceutical Packaging Market to reach USD 270.4 billion by 2031, Wissen Research

SHERIDAN, Wyo., June 12, 2026 /PRNewswire/ -- According to a new study by Wissen Research, the global sustainable pharmaceutical packaging market is projected to...

In Vitro Toxicology Testing Market worth $20.97 billion by 2031 | MarketsandMarkets™

DELRAY BEACH, Fla., June 12, 2026 /PRNewswire/ -- According to MarketsandMarkets™, the In Vitro Toxicology Testing Market is projected to grow from about USD...

In Vitro Toxicology Testing Market worth $20.97 billion by 2031 | MarketsandMarkets™

DELRAY BEACH, Fla., June 12, 2026 /PRNewswire/ -- According to MarketsandMarkets™, the In Vitro Toxicology Testing Market is projected to grow from about USD...

Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against ADMA Biologics, Inc. (ADMA)

NEW YORK, June 11, 2026 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the District of New Jersey on behalf of all persons or entities who purchased or otherwise acquired ADMA Biologics, Inc. (“ADMA” or the “Company”) (NASDAQ: ADMA) securities between August 9, 2024 and March 25, 2026, inclusive (the “Class Period”).

IMAAVY® (nipocalimab-aahu) demonstrates durable hemoglobin response and rapid onset of effect in pivotal Phase 2/3 study in warm autoimmune hemolytic anemia (wAIHA), an autoantibody-driven...

Patients in the IMAAVY 30 mg/kg treatment groupa achieved statistically significant durable hemoglobin responseb, with mean hemoglobin improvement of at least 1 g/dL as...

ROSEN, THE FIRST FILING FIRM, Encourages ADMA Biologics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the...

NEW YORK, June 10, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of securities of ADMA Biologics, Inc. (NASDAQ: ADMA) between August 9, 2024 and March 25, 2026, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 10, 2026 in the securities class action first filed by the Firm.

Humacyte, Inc. Announces Pricing of Public Offering of Common Stock

DURHAM, N.C., June 10, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced the pricing of an underwritten public offering of 47,619,048 shares of its common stock at a public offering price of $1.05 per share. The aggregate gross proceeds from this offering are expected to be $50 million, before deducting underwriting discounts and commissions and other offering expenses payable by Humacyte. The closing of the offering is expected to occur on or about June 12, 2026, subject to the satisfaction of customary closing conditions. In addition, Humacyte has granted the underwriters an option for a period of 30 days to purchase up to an additional 7,142,857 shares of Humacyte’s common stock at the public offering price, less underwriting discounts and commissions. All of the shares of common stock are being sold by Humacyte.

GlycoNex Announces Positive Topline Results for Phase III Clinical Trial of Denosumab Biosimilar SPD8

NEW TAIPEI CITY, June 10, 2026 /PRNewswire/ -- GlycoNex, Inc. (4168, hereinafter referred to as GNX), today announced that the Phase III clinical trial...

ADMA LAWSUIT: ADMA Biologics, Inc. Sued For Securities Fraud; Investors Should Contact Block & Leviton to Possibly Recover Losses

Block & Leviton announces a securities fraud lawsuit has been filed against ADMA Biologics. Investors should contact Block & Leviton by 8/10/2026.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsBiologics

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers